Skip to main content
Erschienen in:

13.10.2022

The Significance of RAS-Like Mutations and MicroRNA Profiling in Predicting Malignancy in Thyroid Biopsy Specimens

verfasst von: Nicole A. Cipriani, Daniel N. Johnson, David H. Sarne, Peter Angelos, Ward Reeves, Tatjana Antic

Erschienen in: Endocrine Pathology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

In cytologically indeterminate thyroid nodules undergoing molecular testing, estimated risk of malignancy is variable. Identification of a non-cancer-specific mutation (RAS-like) confirms a neoplastic process but does not differentiate between benign, malignant, and low-risk neoplasms. This study aims to retrospectively evaluate institutional experience of Interpace (ThyGeNEXT® and ThyraMIR®; Pittsburgh, PA) testing and to determine the rate of malignancy in resected nodules, stratified by mutational analysis and microRNA profile. Of 1917 fine need aspirations, 140 (7.3%) underwent Interpace testing: 47 (33.6%) were molecular-not-benign (harbored mutation, fusion, and/or positive miRNA) and 93 (66.4%) were molecular-benign (no mutations or fusions and negative microRNA). Surgery was spared in 79.6% of molecular-benign and 61.4% of all tested patients. Fifty-four (38.6%) underwent resection. Seventeen (89.5%) of the resected molecular-benign were benign and 2 were malignant. Thirteen (37.1%) of the resected molecular-not-benign were benign, 7 (20%) were noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and 15 (42.9%) were malignant (p < 0.05, negative predictive value (NPV) 89.4–95.6%, positive predictive value (PPV) 22.3–42.8%). Most molecular-not-benign (72.3%) had RAS-like mutation. Twenty-three were resected: 3 were malignant and 7 were NIFTP. Nodules with non-RAS-like mutations (BRAF V600E-like, others) were more likely to be malignant than RAS-like (H/N/KRAS, BRAF K601E) (p < 0.05, NPV 86.9–96.5%, PPV 100%). Most nodules had RAS-like mutations and most were benign or low-risk neoplasms (NIFTP). This study supports the role of histologic examination in the distinction of malignancy in RAS-like thyroid neoplasms and underscores the role of molecular testing in risk stratification, patient counseling, and operative management.
Literatur
1.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133. https://​doi.​org/​10.​1089/​thy.​2015.​0020CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Nishino M, Bellevicine C, Baloch Z (2021) Molecular Tests for Risk-Stratifying Cytologically Indeterminate Thyroid Nodules: An Overview of Commercially Available Testing Platforms in the United States. Journal of Molecular Pathology 2:135–146. https://doi.org/10.3390/jmp2020014CrossRef Nishino M, Bellevicine C, Baloch Z (2021) Molecular Tests for Risk-Stratifying Cytologically Indeterminate Thyroid Nodules: An Overview of Commercially Available Testing Platforms in the United States. Journal of Molecular Pathology 2:135–146. https://​doi.​org/​10.​3390/​jmp2020014CrossRef
5.
Zurück zum Zitat Nishino M, Krane JF (2020) Role of Ancillary Techniques in Thyroid Cytology Specimens. Acta Cytologica 64:40–51CrossRefPubMed Nishino M, Krane JF (2020) Role of Ancillary Techniques in Thyroid Cytology Specimens. Acta Cytologica 64:40–51CrossRefPubMed
8.
10.
Zurück zum Zitat Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, Behera M, Bernard B, Beroukhim R, Bishop JA, Black AD, Bodenheimer T, Boice L, Bootwalla MS, Bowen J, Bowlby R, Bristow CA, Brookens R, Brooks D, Bryant R, Buda E, Butterfield YSN, Carling T, Carlsen R, Carter SL, Carty SE, Chan TA, Chen AY, Cherniack AD, Cheung D, Chin L, Cho J, Chu A, Chuah E, Cibulskis K, Ciriello G, Clarke A, Clayman GL, Cope L, Copland JA, Covington K, Danilova L, Davidsen T, Demchok JA, DiCara D, Dhalla N, Dhir R, Dookran SS, Dresdner G, Eldridge J, Eley G, El-Naggar AK, Eng S, Fagin JA, Fennell T, Ferris RL, Fisher S, Frazer S, Frick J, Gabriel SB, Ganly I, Gao J, Garraway LA, Gastier-Foster JM, Getz G, Gehlenborg N, Ghossein R, Gibbs RA, Giordano TJ, Gomez-Hernandez K, Grimsby J, Gross B, Guin R, Hadjipanayis A, Harper HA, Hayes DN, Heiman DI, Herman JG, Hoadley KA, Hofree M, Holt RA, Hoyle AP, Huang FW, Huang M, Hutter CM, Ideker T, Iype L, Jacobsen A, Jefferys SR, Jones CD, Jones SJM, Kasaian K, Kebebew E, Khuri FR, Kim J, Kramer R, Kreisberg R, Kucherlapati R, Kwiatkowski DJ, Ladanyi M, Lai PH, Laird PW, Lander E, Lawrence MS, Lee D, Lee E, Lee S, Lee W, Leraas KM, Lichtenberg TM, Lichtenstein L, Lin P, Ling S, Liu J, Liu W, Liu Y, LiVolsi VA, Lu Y, Ma Y, Mahadeshwar HS, Marra MA, Mayo M, McFadden DG, Meng S, Meyerson M, Mieczkowski PA, Miller M, Mills G, Moore RA, Mose LE, Mungall AJ, Murray BA, Nikiforov YE, Noble MS, Ojesina AI, Owonikoko TK, Ozenberger BA, Pantazi A, Parfenov M, Park PJ, Parker JS, Paull EO, Pedamallu CS, Perou CM, Prins JF, Protopopov A, Ramalingam SS, Ramirez NC, Ramirez R, Raphael BJ, Rathmell WK, Ren X, Reynolds SM, Rheinbay E, Ringel MD, Rivera M, Roach J, Robertson AG, Rosenberg MW, Rosenthal M, Sadeghi S, Saksena G, Sander C, Santoso N, Schein JE, Schultz N, Schumacher SE, Seethala RR, Seidman J, Senbabaoglu Y, Seth S, Sharpe S, Shaw KRM, Shen JP, Shen R, Sherman S, Sheth M, Shi Y, Shmulevich I, Sica GL, Simons J v., Sinha R, Sipahimalani P, Smallridge RC, Sofia HJ, Soloway MG, Song X, Sougnez C, Stewart C, Stojanov P, Stuart JM, Sumer SO, Sun Y, Tabak B, Tam A, Tan D, Tang J, Tarnuzzer R, Taylor BS, Thiessen N, Thorne L, Thorsson V, Tuttle RM, Umbricht CB, van den Berg DJ, Vandin F, Veluvolu U, Verhaak RGW, Vinco M, Voet D, Walter V, Wang Z, Waring S, Weinberger PM, Weinhold N, Weinstein JN, Weisenberger DJ, Wheeler D, Wilkerson MD, Wilson J, Williams M, Winer DA, Wise L, Wu J, Xi L, Xu AW, Yang L, Yang L, Zack TI, Zeiger MA, Zeng D, Zenklusen JC, Zhao N, Zhang H, Zhang J, Zhang J, Zhang W, Zmuda E, Zou L (2014) Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159:676–690. https://doi.org/10.1016/j.cell.2014.09.050CrossRefPubMedCentral Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, Behera M, Bernard B, Beroukhim R, Bishop JA, Black AD, Bodenheimer T, Boice L, Bootwalla MS, Bowen J, Bowlby R, Bristow CA, Brookens R, Brooks D, Bryant R, Buda E, Butterfield YSN, Carling T, Carlsen R, Carter SL, Carty SE, Chan TA, Chen AY, Cherniack AD, Cheung D, Chin L, Cho J, Chu A, Chuah E, Cibulskis K, Ciriello G, Clarke A, Clayman GL, Cope L, Copland JA, Covington K, Danilova L, Davidsen T, Demchok JA, DiCara D, Dhalla N, Dhir R, Dookran SS, Dresdner G, Eldridge J, Eley G, El-Naggar AK, Eng S, Fagin JA, Fennell T, Ferris RL, Fisher S, Frazer S, Frick J, Gabriel SB, Ganly I, Gao J, Garraway LA, Gastier-Foster JM, Getz G, Gehlenborg N, Ghossein R, Gibbs RA, Giordano TJ, Gomez-Hernandez K, Grimsby J, Gross B, Guin R, Hadjipanayis A, Harper HA, Hayes DN, Heiman DI, Herman JG, Hoadley KA, Hofree M, Holt RA, Hoyle AP, Huang FW, Huang M, Hutter CM, Ideker T, Iype L, Jacobsen A, Jefferys SR, Jones CD, Jones SJM, Kasaian K, Kebebew E, Khuri FR, Kim J, Kramer R, Kreisberg R, Kucherlapati R, Kwiatkowski DJ, Ladanyi M, Lai PH, Laird PW, Lander E, Lawrence MS, Lee D, Lee E, Lee S, Lee W, Leraas KM, Lichtenberg TM, Lichtenstein L, Lin P, Ling S, Liu J, Liu W, Liu Y, LiVolsi VA, Lu Y, Ma Y, Mahadeshwar HS, Marra MA, Mayo M, McFadden DG, Meng S, Meyerson M, Mieczkowski PA, Miller M, Mills G, Moore RA, Mose LE, Mungall AJ, Murray BA, Nikiforov YE, Noble MS, Ojesina AI, Owonikoko TK, Ozenberger BA, Pantazi A, Parfenov M, Park PJ, Parker JS, Paull EO, Pedamallu CS, Perou CM, Prins JF, Protopopov A, Ramalingam SS, Ramirez NC, Ramirez R, Raphael BJ, Rathmell WK, Ren X, Reynolds SM, Rheinbay E, Ringel MD, Rivera M, Roach J, Robertson AG, Rosenberg MW, Rosenthal M, Sadeghi S, Saksena G, Sander C, Santoso N, Schein JE, Schultz N, Schumacher SE, Seethala RR, Seidman J, Senbabaoglu Y, Seth S, Sharpe S, Shaw KRM, Shen JP, Shen R, Sherman S, Sheth M, Shi Y, Shmulevich I, Sica GL, Simons J v., Sinha R, Sipahimalani P, Smallridge RC, Sofia HJ, Soloway MG, Song X, Sougnez C, Stewart C, Stojanov P, Stuart JM, Sumer SO, Sun Y, Tabak B, Tam A, Tan D, Tang J, Tarnuzzer R, Taylor BS, Thiessen N, Thorne L, Thorsson V, Tuttle RM, Umbricht CB, van den Berg DJ, Vandin F, Veluvolu U, Verhaak RGW, Vinco M, Voet D, Walter V, Wang Z, Waring S, Weinberger PM, Weinhold N, Weinstein JN, Weisenberger DJ, Wheeler D, Wilkerson MD, Wilson J, Williams M, Winer DA, Wise L, Wu J, Xi L, Xu AW, Yang L, Yang L, Zack TI, Zeiger MA, Zeng D, Zenklusen JC, Zhao N, Zhang H, Zhang J, Zhang J, Zhang W, Zmuda E, Zou L (2014) Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell 159:676–690. https://​doi.​org/​10.​1016/​j.​cell.​2014.​09.​050CrossRefPubMedCentral
11.
Zurück zum Zitat Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology 33:27–63CrossRefPubMed Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology 33:27–63CrossRefPubMed
12.
Zurück zum Zitat Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD, Larsen PR, Marqusee E, Alexander EK (2006) Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. Journal of Clinical Endocrinology and Metabolism 91:3411–3417. https://doi.org/10.1210/jc.2006-0690CrossRefPubMed Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD, Larsen PR, Marqusee E, Alexander EK (2006) Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. Journal of Clinical Endocrinology and Metabolism 91:3411–3417. https://​doi.​org/​10.​1210/​jc.​2006-0690CrossRefPubMed
13.
Zurück zum Zitat Johnson DN, Cavallo AB, Uraizee I, Tanager K, Lastra RR, Antic T, Cipriani NA (2019) A Proposal for Separation of Nuclear Atypia and Architectural Atypia in Bethesda Category III (AUS/FLUS) Based on Differing Rates of Thyroid Malignancy. American Journal of Clinical Pathology 151:. https://doi.org/10.1093/ajcp/aqy109CrossRefPubMed Johnson DN, Cavallo AB, Uraizee I, Tanager K, Lastra RR, Antic T, Cipriani NA (2019) A Proposal for Separation of Nuclear Atypia and Architectural Atypia in Bethesda Category III (AUS/FLUS) Based on Differing Rates of Thyroid Malignancy. American Journal of Clinical Pathology 151:. https://​doi.​org/​10.​1093/​ajcp/​aqy109CrossRefPubMed
14.
Zurück zum Zitat Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, Sadow PM, Krane JF, Stack BC, Zafereo ME, Ali SZ, Weitzman SP, Hao Y, Babiarz JE, Kennedy GC, Kloos RT (2021) Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism 106:2198–2207. https://doi.org/10.1210/clinem/dgab304CrossRefPubMedPubMedCentral Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, Sadow PM, Krane JF, Stack BC, Zafereo ME, Ali SZ, Weitzman SP, Hao Y, Babiarz JE, Kennedy GC, Kloos RT (2021) Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism 106:2198–2207. https://​doi.​org/​10.​1210/​clinem/​dgab304CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kakudo K (2022) Different Threshold of Malignancy for RAS-like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice. Cancers (Basel) 14 Kakudo K (2022) Different Threshold of Malignancy for RAS-like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice. Cancers (Basel) 14
17.
Zurück zum Zitat Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, Barletta JA, Wenig BM, Ghuzlan A al, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd R v., Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Michael TR, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA (2016) Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncology 2:1023–1029. https://doi.org/10.1001/jamaoncol.2016.0386CrossRefPubMedPubMedCentral Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, Barletta JA, Wenig BM, Ghuzlan A al, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd R v., Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Michael TR, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA (2016) Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncology 2:1023–1029. https://​doi.​org/​10.​1001/​jamaoncol.​2016.​0386CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Nikiforov YE, Baloch ZW, Hodak SP, Giordano TJ, Lloyd R v., Seethala RR, Wenig BM (2018) Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncology 4:1125–1126CrossRefPubMedPubMedCentral Nikiforov YE, Baloch ZW, Hodak SP, Giordano TJ, Lloyd R v., Seethala RR, Wenig BM (2018) Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncology 4:1125–1126CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Patel SG, Carty SE, McCoy KL, Ohori NP, LeBeau SO, Seethala RR, Nikiforova MN, Nikiforov YE, Yip L (2017) Preoperative detection of RAS mutation may guide extent of thyroidectomy. In: Surgery (United States) Patel SG, Carty SE, McCoy KL, Ohori NP, LeBeau SO, Seethala RR, Nikiforova MN, Nikiforov YE, Yip L (2017) Preoperative detection of RAS mutation may guide extent of thyroidectomy. In: Surgery (United States)
21.
Zurück zum Zitat Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, Yip L, LeBeau SO, McCoy KL, Coyne C, Stang MT, Johnson J, Ferris RL, Seethala R, Nikiforov YE, Hodak SP (2013) RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. Journal of Clinical Endocrinology and Metabolism 98:. https://doi.org/10.1210/jc.2012-3396CrossRefPubMedPubMedCentral Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, Yip L, LeBeau SO, McCoy KL, Coyne C, Stang MT, Johnson J, Ferris RL, Seethala R, Nikiforov YE, Hodak SP (2013) RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. Journal of Clinical Endocrinology and Metabolism 98:. https://​doi.​org/​10.​1210/​jc.​2012-3396CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Radkay LA, Chiosea SI, Seethala RR, Hodak SP, Lebeau SO, Yip L, McCoy KL, Carty SE, Schoedel KE, Nikiforova MN, Nikiforov YE, Ohori NP (2014) Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathology 122:873–882. https://doi.org/10.1002/cncy.21474CrossRefPubMed Radkay LA, Chiosea SI, Seethala RR, Hodak SP, Lebeau SO, Yip L, McCoy KL, Carty SE, Schoedel KE, Nikiforova MN, Nikiforov YE, Ohori NP (2014) Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathology 122:873–882. https://​doi.​org/​10.​1002/​cncy.​21474CrossRefPubMed
26.
Zurück zum Zitat Stence AA, Gailey MP, Robinson RA, Jensen CS, Ma D (2015) Simultaneously Detection of 50 Mutations at 20 Sites in the BRAF and RAS Genes by Multiplexed Single-Nucleotide Primer Extension Assay Using Fine-Needle Aspirates of Thyroid Nodules Stence AA, Gailey MP, Robinson RA, Jensen CS, Ma D (2015) Simultaneously Detection of 50 Mutations at 20 Sites in the BRAF and RAS Genes by Multiplexed Single-Nucleotide Primer Extension Assay Using Fine-Needle Aspirates of Thyroid Nodules
27.
Zurück zum Zitat Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN (2011) Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. Journal of Clinical Endocrinology and Metabolism 96:3390–3397. https://doi.org/10.1210/jc.2011-1469CrossRefPubMedPubMedCentral Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN (2011) Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. Journal of Clinical Endocrinology and Metabolism 96:3390–3397. https://​doi.​org/​10.​1210/​jc.​2011-1469CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ontario Health (Quality) (2022) Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment. Ontario Health Technology Assessment Series 22:1–111 Ontario Health (Quality) (2022) Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment. Ontario Health Technology Assessment Series 22:1–111
37.
Zurück zum Zitat Angell TE (2017) RAS- positive thyroid nodules. Current Opinion in Endocrinology, Diabetes and Obesity 24 Angell TE (2017) RAS- positive thyroid nodules. Current Opinion in Endocrinology, Diabetes and Obesity 24
38.
Zurück zum Zitat Marotta V, Bifulco M, Vitale M (2021) Significance of ras mutations in thyroid benign nodules and non‐medullary thyroid cancer. Cancers (Basel) 13 Marotta V, Bifulco M, Vitale M (2021) Significance of ras mutations in thyroid benign nodules and non‐medullary thyroid cancer. Cancers (Basel) 13
39.
Zurück zum Zitat Xing M (2016) Clinical utility of RAS mutations in thyroid cancer: A blurred picture now emerging clearer. BMC Medicine 14 Xing M (2016) Clinical utility of RAS mutations in thyroid cancer: A blurred picture now emerging clearer. BMC Medicine 14
Metadaten
Titel
The Significance of RAS-Like Mutations and MicroRNA Profiling in Predicting Malignancy in Thyroid Biopsy Specimens
verfasst von
Nicole A. Cipriani
Daniel N. Johnson
David H. Sarne
Peter Angelos
Ward Reeves
Tatjana Antic
Publikationsdatum
13.10.2022
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2022
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-022-09734-0

Neu im Fachgebiet Pathologie

Overview of a comparative analysis of microsatellite instability and standard mismatch repair protein-deficiency tests in a large cancer cohort

  • Hauptreferate: Hauptprogramm der DGP

A retrospective analysis was carried out based on a large cancer patient cohort of our institute ( n  = 1306; collected from 2018 to 2023). dMMR was tested by four IHC reactions (MLH1 and PMS2 or MSH2 and MSH 6). Further, parallel pentaplex …

Molekulare Testung bei mesenchymalen Neoplasien: Was, wann und wie testen?

Mit dem weit verbreiteten Einsatz diverser molekularer Methoden in der histopathologischen Routinediagnostik hat die Tumorklassifikation in den letzten beiden Jahrzehnten signifikante Fortschritte gemacht. Dabei wurden zum einen zahlreiche …

Reconstructing 3D histological structures using machine learning (artificial intelligence) algorithms

  • Hauptreferate: Hauptprogramm der DGP

Artificial intelligence (AI) has recently been applied to pathological and medical image analysis with high sensitivity and specificity [ 1 , 2 ], aiding in various dental diagnostic techniques. The use of AI in image annotation has enhanced the …

Key considerations when implementing new diagnostic technologies in routine practice

  • Hauptreferate: Arbeitsgemeinschaften der DGP

This review explores several key considerations that are critical for implementing new diagnostic technologies into routine practice. These elements will provide a comprehensive guide for navigating the complexities of integrating cutting-edge …